By contrast, the ctDNA, which is the younger counterpart of CTCs, has been successfully integrated into regular clinical procedures following the approval of the EGFR mutation test (Therascreen EGFR Plasma, Qiagen) by the European Medicines Agency (EMA) in the plasma of patients diagnosed with non-small cell lung cancer (NSCLC) [11]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.